Roche's companion Dx for lung cancer drug wins FDA nod

05/15/2013 | Medscape (free registration) · Fox Business

The FDA has approved Roche's cobas EGFR Mutation Test as a companion diagnostic for Tarceva, or erlotinib, a nonsmall-cell lung cancer drug developed by Roche's Genentech unit. The test, designed to determine which patients will benefit from Tarceva, is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor mutations found in around 10% of nonsmall-cell lung cancer.

View Full Article in:

Medscape (free registration) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ